Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.34 |
| ▸ | HRH2 | P25021 | 5/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9537257 | 0.95 | CA1 (0.35) | HRH3HRH2SIGMAR1IDH1 | |
| SCHEMBL10297726 | 0.89 | IDH1 (0.32) | IDH1 | |
| SCHEMBL12015843 | 0.78 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL13518618 | 0.77 | CHRNB2 (0.30) | CHRNB2CHRNA4 | |
| SCHEMBL10297582 | 0.77 | CXCR4 (0.32) | CHRNB2CHRNA4 | |
| SCHEMBL21344917 | 0.74 | IDH1 (0.33) | IDH1 | |
| SCHEMBL20851571 | 0.73 | CXCR4 (0.37) | HRH3HRH2 | |
| SCHEMBL12346329 | 0.73 | CXCR4 (0.37) | HRH3HRH2 | |
| SCHEMBL1688215 | 0.73 | CXCR4 (0.37) | HRH3HRH2 | |
| SCHEMBL12162482 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9079890-B2 | Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives | ARRAY BIOPHARMA INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150057448-A1 | INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES | ARRAY BIOPHARMA, INC. | 2015-02-26 | — | — | US | disclosed |
| US-8853409-B2 | Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8212045-B2 | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA INC. (US) | 2010-08-12 | — | — | US | disclosed |
| EP-0337944-B1 | UREAS | CIBA-GEIGY AG (CH) | 1993-07-28 | — | — | EP | disclosed |
| US-4973690-A | PYRIMIDIN-2-YL UREAS, HERBICICES, PLANT GROWTH REGULATORS | CIBA-GEIGY CORPORATION (US) | 1990-11-27 | — | — | US | disclosed |
| EP-0337944-A1 | Ureas | CIBA-GEIGY AG (CH) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | HRH3 2028/4885HRH2 3675/4885CHRNB2 3564/4885 |
| US-20150057448-A1 | INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES | PDXK, IL4I1, CDK2 | HRH3 828/4885HRH2 1098/4885CHRNB2 1562/4885 |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | HRH3 2884/4885HRH2 2411/4885CHRNB2 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.